Table 2.
Availability and affordability of 49 selected cancer medicines in public hospitals and private pharmacies
| Availability | Affordabilitya | ||||
|---|---|---|---|---|---|
| No. | Medicine | Public Sector (n = 21) | Private Sector (n = 19) | Public Sector (n = 21) | Private Sectorb(n = 19) |
| 1 | Anastrozole 1 mg tab | 76.19% | 89.47% | 0.24 | 0.59 |
| 2 | Bevacizumab 100 mg inj | 42.86% | 73.68% | 30.12 | 57.68 |
| 3 | Bevacizumab 400 mg inj | 66.67% | 68.42% | 29.42 | 51.99 |
| 4 | Capecitabine 500 mg tab | 76.19% | 78.95% | 1.88 | 5.50 |
| 5 | Carboplatin 150 mg inj | 85.71% | 68.42% | 0.44 | 0.83 |
| 6 | Cetuximab 5 mg/ml inj | 38.10% | 36.84% | 35.74 | 62.88 |
| 7 | Cyclophosphamide 200 mg inj | 80.95% | 84.21% | 0.48 | 0.67 |
| 8 | Cyclophosphamide 500 mg inj | 95.24% | 73.68% | 0.53 | 0.64 |
| 9 | Cytarabine 500 mg inj | 95.24% | 84.21% | ||
| 10 | Dasatinib 50 mg tab | 4.76% | 31.58% | 17.20 | 33.95 |
| 11 | Daunorubicin 20 mg inj | 66.67% | 63.16% | ||
| 12 | Docetaxel 20 mg/1 ml inj | 66.67% | 78.95% | 5.26 | 8.00 |
| 13 | Docetaxel 80 mg/4 ml inj | 71.43% | 84.21% | 3.78 | 6.59 |
| 14 | Doxorubicin 10 mg inj | 85.71% | 73.68% | 0.61 | 1.09 |
| 15 | Doxorubicin 50 mg inj | 85.71% | 84.21% | 0.45 | 0.57 |
| 16 | Epirubicin 10 mg/5 ml inj | 42.86% | 63.16% | 3.00 | |
| 17 | Epirubicin 50 mg/25 ml inj | 61.90% | 84.21% | 0.57 | 1.86 |
| 18 | Etoposide 20 mg/ml inj | 95.24% | 78.95% | 0.16 | 0.33 |
| 19 | Everolimus 10 mg tab | 14.29% | 42.11% | 21.26 | 30.17 |
| 20 | Everolimus 5 mg tab | 9.52% | 42.11% | 30.17 | |
| 21 | Exemestane 25 mg tab | 85.71% | 78.95% | 1.02 | 0.73 |
| 22 | Fluorouracil 250 mg inj | 80.95% | 52.63% | 0.10 | 0.16 |
| 23 | Folinic Acid 50 mg/4 ml inj | 95.24% | 63.16% | ||
| 24 | Folinic Acid 15 mg tab | 42.86% | 57.89% | ||
| 25 | Gemcitabine 1 g inj | 76.19% | 78.95% | 1.09 | 4.86 |
| 26 | Ifosfamide 1 g inj | 85.71% | 73.68% | 3.15 | 5.50 |
| 27 | Imatinib 100 mg tab | 33.33% | 63.16% | 3.58 | 17.59 |
| 28 | Imatinib 400 mg tab | 38.10% | 47.37% | 3.43 | 18.63 |
| 29 | Irinotecan 20 mg/ml inj | 76.19% | 68.42% | 3.18 | 7.25 |
| 30 | L-Asparaginase 10,000 IU inj | 76.19% | 84.21% | 13,15 | 17.03 |
| 31 | Letrozole 2.5 mg tab | 66.67% | 84.21% | 0.20 | 0.44 |
| 32 | Mercaptopurine 50 mg tab | 52.38% | 84.21% | 1.45 | 2.38 |
| 33 | Methotrexate 2.5 mg tab | 71.43% | 84.21% | 0.02 | 0.07 |
| 34 | Methotrexate 500 mg inj | 80.95% | 78.95% | 0.02 | 0.02 |
| 35 | Methotrexate 50 mg inj | 95.24% | 68.42% | 0.06 | 0.11 |
| 36 | Nilotinib 200 mg tab | 23.81% | 36.84% | 21.72 | |
| 37 | Oxaliplatin 100 mg/20 ml inj | 61.90% | 84.21% | 0.89 | 2.36 |
| 38 | Oxaliplatin 50 mg/10 ml inj | 57.14% | 73.68% | 1.25 | 2.40 |
| 39 | Paclitaxel 6 mg/ml inj | 80.95% | 78.95% | 0.45 | 1.63 |
| 40 | Panitimumab 20 mg/ml inj | 28.57% | 42.11% | 31.72 | 58.93 |
| 41 | Pazopanib 200 mg tab | 9.52% | 26.32% | 14.89 | |
| 42 | Pazopanib 400 mg tab | 4.76% | 52.63% | 8.49 | 14.89 |
| 43 | Rituximab 100 mg/10 ml inj | 61.90% | 68.42% | 6.65 | 30.97 |
| 44 | Rituximab 500 mg/50 ml inj | 71.43% | 68.42% | 4.65 | 30.96 |
| 45 | Sorafenib 200 mg tab | 19.05% | 57.89% | 19.59 | 31.13 |
| 46 | Sunitinib 12.5 mg tab | 14.29% | 47.37% | 11.89 | 25.10 |
| 47 | Tamoxifen 20 mg tab | 90.48% | 78.95% | 0.02 | 0.06 |
| 48 | Trastuzumab 440 mg inj | 71.40% | 57.89% | 13.77 | 23.63 |
| 49 | Vincristine 1 mg inj | 85.71% | 78.95% | 0.35 | 0.45 |
| Mean availability/Median affordability | 61.20% | 67.45% | 1.45 | 5.50 | |
| Mean availability/Median affordability: | |||||
| Breast cancer medicines | 74.8% | 78.1% | 0.57 | 1.36 | |
| Leukemia medicines | 59.3% | 66.4% | 3.50 | 17.72 | |
| Colorectal cancer medicines | 55.6% | 58.3% | 2.53 | 6.37 | |
| Renal cancer medicines | 52.0% | 61.9% | 1.09 | 17.72 | |
tab tablet, inj injectable, mg milligrams, ml milliliters, IU international unit, n number of facilities surveyed and included in the analysis
aAffordability is expressed as number of days needed to purchase 1 day of treatment based in minimum daily wage
bAffordability in the private sector: we present only the affordability of the lowest priced generic medicines. For medicines with no generic alternatives, we present the affordability of the patented/originator medicine